ATRA
Income statement / Annual
Last year (2023), Atara Biotherapeutics, Inc.'s total revenue was $8.57 M,
a decrease of 86.51% from the previous year.
In 2023, Atara Biotherapeutics, Inc.'s net income was -$276.13 M.
See Atara Biotherapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$8.57 M
|
$63.57 M
|
$20.34 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$8.89 M |
$14.57 M |
$11.38 M |
$9.87 M |
$8.11 M |
$3.78 M |
$956,000.00 |
$383,000.00 |
$48,000.00 |
$0.00 |
| Gross Profit |
-$313,000.00 |
$49.01 M |
$8.96 M |
-$9.87 M |
-$8.11 M |
-$3.78 M |
-$956,000.00 |
-$383,000.00 |
-$48,000.00 |
$0.00 |
| Gross Profit Ratio |
-0.04 |
0.77 |
0.44 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$224.79 M
|
$272.53 M
|
$282.00 M
|
$244.65 M
|
$216.10 M
|
$167.46 M
|
$81.21 M
|
$56.51 M
|
$41.62 M
|
$15.45 M
|
| General & Administrative
Expenses |
$50.91 M
|
$71.55 M
|
$78.80 M
|
$64.40 M
|
$79.58 M
|
$69.65 M
|
$40.33 M
|
$24.73 M
|
$16.83 M
|
$12.71 M
|
| Selling & Marketing
Expenses |
-$1.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$49.80 M
|
$71.55 M
|
$78.80 M
|
$64.40 M
|
$79.58 M
|
$69.65 M
|
$40.33 M
|
$24.73 M
|
$16.83 M
|
$12.71 M
|
| Other Expenses |
$0.00 |
-$700,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.07 M |
| Operating Expenses |
$275.69 M |
$344.09 M |
$360.80 M |
$309.05 M |
$295.68 M |
$237.11 M |
$121.53 M |
$81.24 M |
$58.45 M |
$28.16 M |
| Cost And Expenses |
$284.58 M |
$344.09 M |
$360.80 M |
$309.05 M |
$295.68 M |
$237.11 M |
$121.53 M |
$81.24 M |
$58.45 M |
$28.16 M |
| Interest Income |
$5.43 M |
$1.99 M |
$367,000.00 |
$2.45 M |
$4.72 M |
$6.37 M |
$2.03 M |
$2.20 M |
$1.22 M |
$125,000.00 |
| Interest Expense |
$5.29 M |
$1.99 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$4.83 M
|
$14.57 M
|
$11.38 M
|
$9.87 M
|
$8.11 M
|
$3.78 M
|
$956,000.00
|
$383,000.00
|
$48,000.00
|
$6,000.00
|
| EBITDA |
-$266.00 M
|
-$213.72 M
|
-$331.12 M
|
-$296.74 M
|
-$282.86 M
|
-$233.33 M
|
-$120.58 M
|
-$80.86 M
|
-$58.40 M
|
-$28.15 M
|
| EBITDA Ratio |
-31.03 |
-5.2 |
-16.74 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-32.19
|
-4.41
|
-16.74
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$105,000.00
|
$52.22 M
|
$367,000.00
|
$2.45 M
|
$4.72 M
|
$6.37 M
|
$2.03 M
|
$2.20 M
|
$1.22 M
|
$125,000.00
|
| Income Before Tax |
-$276.11 M |
-$228.29 M |
-$340.10 M |
-$306.61 M |
-$290.96 M |
-$230.74 M |
-$119.51 M |
-$79.04 M |
-$57.23 M |
-$28.03 M |
| Income Before Tax Ratio
|
-32.21
|
-3.59
|
-16.72
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$15,000.00 |
$12,000.00 |
$46,000.00 |
$15,000.00 |
$12,000.00 |
-$44,000.00 |
-$14,000.00 |
$10,000.00 |
-$9,000.00 |
-$25,000.00 |
| Net Income |
-$276.13 M |
-$2.28 B |
-$3.40 B |
-$3.07 B |
-$2.91 B |
-$2.31 B |
-$1.19 B |
-$790.49 M |
-$572.21 M |
-$280.06 M |
| Net Income Ratio |
-32.21 |
-35.91 |
-167.23 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-65.18 |
-55.96 |
-90.78 |
-103.63 |
-141.78 |
-131.64 |
-100.03 |
-68.78 |
-55.92 |
-140.42 |
| EPS Diluted |
-65.18 |
-55.96 |
-90.78 |
-103.63 |
-141.78 |
-131.64 |
-100.03 |
-68.78 |
-55.92 |
-140.42 |
| Weighted Average Shares
Out |
$4.24 M
|
$4.08 M
|
$3.75 M
|
$2.96 M
|
$2.05 M
|
$1.75 M
|
$1.19 M
|
$1.15 M
|
$1.02 M
|
$199,440.00
|
| Weighted Average Shares
Out Diluted |
$4.24 M
|
$4.08 M
|
$3.75 M
|
$2.96 M
|
$2.05 M
|
$1.75 M
|
$1.19 M
|
$1.15 M
|
$1.02 M
|
$199,440.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
